In od c ion

A (CO ID-19) 1, . I L 2020, 86% 2,500 CO ID-19 198 E 2 , CO ID-19 -3 . S -CO ID 19 H CO ID-19 .

Me hod

Da a o ce and ea ch a eg y

P M , C C , MEDLINE P R L S R M - A (PRISMA) – CO ID– (1) , (2) >18 , (3) E , (4) (RC) . S D 2019 J 2021 A I .

S d y Selec ion

I : 1) >18 ; 2) CO ID-19 (R -PCR); 3) R 4). A S (AS)- >3 . P : 1) , 2) , 3) , 4) CO ID-19, (5) .

Da a E ac ion

(= 12)

D 10

Q ali y A e men

7 C : S C H P .

O come Mea e

>3 AS- .

S a i ical Anal y i

R M 5.4.1. F P (OR) 95% (CI) 95% CI 1. 2 - Q P 0.1 I .

C C 1 (F 1). F 2. 2. (C CO ID- 19 : A ; M CO ID-19 : A)

Cha ac e i ic of he Incl ded S die and Pa ien

177 1. 2020 2021 I A S (AS) A S (AS) 0, 10, 10 A 20 ( ) (1).

Q ali y of S die



Figure 1 :

2. A >90% I (2, F 2)

Co ico e oid e ec in he eco e y of olfac o y f nc ion of COVID-19 pa ien

P O R (= 177) 0.48 (0.26, 0.87) (CI = 0.30, 1.47; 0.12, 0.76). (I2=39%).

Sen i i i y anal y i

Di c ion

CO ID-19 15 20 H CO ID-19 CO ID-19 .4 A K CO ID-19 CO ID-19 .7 S CO ID-19 -CO ID